FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of veterinary internal medicine2025; 39(4); e70143; doi: 10.1111/jvim.70143

Markers of Hepatic Insulin Clearance and Their Association With Steatosis in Hyperinsulinaemic Horses.

Abstract: Hyperinsulinaemia (HI) is an important feature of Equine Metabolic Syndrome (EMS). It has been suggested that reduced hepatic clearance of insulin contributes to HI, particularly in humans affected by metabolic dysfunction-associated steatotic liver disease (MASLD). Objective: In obese horses with HI, insulin clearance is impaired and associated with MASLD. Methods: Tissue samples were collected at post-mortem from clinically well-characterized horses with HI (n = 13; basal insulin > 20 mIU/l) and without HI (control; n = 20). Methods: Retrospective observational study. Molecular drivers of hepatic clearance (CAECAM-1, an insulin chaperone protein and IDE-Insulin Degrading Enzyme) were quantified by RT-qPCR and activity, respectively, in liver tissue. Fixed liver sections stained with hematoxylin and eosin (H&E) were assigned a histological score by two blinded observers using an equine liver disease score and a human MASLD score. Triglyceride (TG) content in liver sections, serum liver enzymes, ACTH, basal insulin, and serum triglycerides were also measured. Results: IDE activity was 2.73 (IQR 4.00 activity/mg of protein) in HI horses and 2.18 (IQR 0.55) in controls (p = 0.07). IDE activity correlated negatively with insulin (rho = 0.561, p = 0.04) but not with liver or serum TG. CEACAM-1 gene expression was higher in the HI group (2.09 ± 1.79 folds) than in controls (0.69 ± 0.62, p = 0.03). Liver disease and MASLD scores were no different between groups, whereas triglyceride liver content was higher in horses with HI (504.83 IQR 217.51 nmol/g) compared to controls (363.58 IQR 67.32 nmol/g, p = 0.04). Conclusions: MASLD is not consistently present in HI horses, but CAECAM-1 expression is higher.
© 2025 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2025-06-06 PubMed ID: 40476757PubMed Central: PMC12143019DOI: 10.1111/jvim.70143Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper investigates how hyperinsulinaemia (abnormally high levels of insulin in the blood) is related to liver disease in obese horses. The study utilized post-mortem tissue samples from horses with and without hyperinsulinaemia to understand how the liver does not properly clear insulin in these cases, potentially contributing to metabolic disease and steatosis (fat accumulation in the liver).

Methodology

The researchers used a combination of techniques and measurements to assess the state of the horses’ health and metabolism:

  • Tissue samples were taken from 13 horses with hyperinsulinaemia and 20 control horses (those without hyperinsulinaemia) post-mortem. Hyperinsulinaemia was defined as a basal insulin level greater than 20 mIU/l.
  • They measured the activity of the Insulin Degrading Enzyme (IDE) and quantity of CEACAM-1, an insulin chaperone protein, believed to be key markers of hepatic insulin clearance.
  • Two blinded observers scored fixed liver sections stained with hematoxylin and eosin using an equine liver disease score and a human steatotic liver disease score (MASLD).
  • They evaluated the triglyceride (a type of fat) content in liver sections and in the horses’ serum (blood without clotting factors).
  • Serum liver enzymes and ACTH (a hormone that controls the body’s response to stress) levels were also noted.

Results

The study revealed key correlations and differences between horses with hyperinsulinaemia and the control group:

  • IDE activity was slightly higher in horses with hyperinsulinaemia, although this difference wasn’t statistically significant (p=0.07).
  • IDE activity negatively correlated with insulin levels.
  • CEACAM-1 gene expression was significantly higher in the HI group compared to the controls, indicating a difference in insulin metabolism.
  • While both groups of horses had similar liver disease and MASLD scores, the hyperinsulinaemia group had a higher triglyceride content in their livers, indicating more fat accumulation.

Conclusions

Contrary to their expectations, the researchers did not find an association between hyperinsulinaemia in horses and the presence of metabolic dysfunction-associated steatotic liver disease (MASLD). This suggests that the relationship between high levels of insulin and abnormal fat accumulation and metabolism in the liver needs further study in equine models. However, they found higher CEACAM-1 expression in horses with hyperinsulinaemia, indicating a potential molecular link between insulin resistance and fat metabolism in the liver.

Cite This Article

APA
Dosi M, Scott L, Payne H, Poldy J, Keen J, McGorum B, Malbon A, Morgan R. (2025). Markers of Hepatic Insulin Clearance and Their Association With Steatosis in Hyperinsulinaemic Horses. J Vet Intern Med, 39(4), e70143. https://doi.org/10.1111/jvim.70143

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 39
Issue: 4
Pages: e70143

Researcher Affiliations

Dosi, Miranda
  • Scotland Rural College, Edinburgh, UK.
Scott, Laura
  • Scotland Rural College, Edinburgh, UK.
Payne, Holly
  • Scotland Rural College, Edinburgh, UK.
Poldy, Jacqueline
  • Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Roslin, UK.
Keen, John
  • Scotland Rural College, Edinburgh, UK.
  • Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Roslin, UK.
McGorum, Bruce
  • Scotland Rural College, Edinburgh, UK.
  • Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Roslin, UK.
Malbon, Alexandra
  • Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Roslin, UK.
Morgan, Ruth
  • Scotland Rural College, Edinburgh, UK.
  • Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Roslin, UK.

MeSH Terms

  • Animals
  • Horses
  • Horse Diseases / metabolism
  • Hyperinsulinism / veterinary
  • Hyperinsulinism / metabolism
  • Insulin / metabolism
  • Retrospective Studies
  • Liver / metabolism
  • Male
  • Fatty Liver / veterinary
  • Fatty Liver / metabolism
  • Female
  • Biomarkers / metabolism
  • Insulysin / metabolism
  • Triglycerides / blood

Conflict of Interest Statement

The authors declare no conflicts of interest.

References

This article includes 39 references
  1. Durham AE, Frank N, McGowan CM. ECEIM Consensus Statement on Equine Metabolic Syndrome. Journal of Veterinary Internal Medicine 33, no. 2 (2019): 335–349.
    doi: 10.1111/jvim.15423pmc: PMC6430910pubmed: 30724412google scholar: lookup
  2. Ader M, Stefanovski D, Kim SP. Hepatic Insulin Clearance Is the Primary Determinant of Insulin Sensitivity in the Normal Dog. Obesity 22, no. 5 (2014): 1238–1245.
    doi: 10.1002/oby.20625pmc: PMC3969862pubmed: 24123967google scholar: lookup
  3. Fosam A, Sikder S, Abel BS. Reduced Insulin Clearance and Insulin‐Degrading Enzyme Activity Contribute to Hyperinsulinemia in African Americans. Journal of Clinical Endocrinology and Metabolism 105, no. 4 (2020): 1835–e1846.
    doi: 10.1210/clinem/dgaa070pmc: PMC7059993pubmed: 32052016google scholar: lookup
  4. Mittelman SD, Van Citters GW, Kim SP. Longitudinal Compensation for Fat‐Induced Insulin Resistance Includes Reduced Insulin Clearance and Enhanced Beta‐Cell Response. Diabetes 49, no. 12 (2000): 2116–2125.
    doi: 10.2337/diabetes.49.12.2116pubmed: 11118015google scholar: lookup
  5. Asare-Bediako I, Paszkiewicz RL, Kim SP. Variability of Directly Measured First‐Pass Hepatic Insulin Extraction and Its Association With Insulin Sensitivity and Plasma Insulin. Diabetes 67, no. 8 (2018): 1495–1503.
    doi: 10.2337/db17-1520pmc: PMC6054441pubmed: 29752425google scholar: lookup
  6. Najjar SM, Perdomo G. Hepatic Insulin Clearance: Mechanism and Physiology. Physiology 34, no. 3 (2019): 198–215.
    doi: 10.1152/physiol.00048.2018pmc: PMC6734066pubmed: 30968756google scholar: lookup
  7. De Laat MA, van Haeften JJ, Sillence MN. The Effect of Oral and Intravenous Dextrose on C‐Peptide Secretion in Ponies. Journal of Animal Science 94, no. 2 (2016): 574–580.
    doi: 10.2527/jas.2015-9817pubmed: 27065127google scholar: lookup
  8. Tóth F, Frank N, Martin-Jiménez T, Elliott SB, Geor RJ, Boston RC. Measurement of C‐Peptide Concentrations and Responses to Somatostatin, Glucose Infusion, and Insulin Resistance in Horses. Equine Veterinary Journal 42, no. 2 (2010): 149–155.
    doi: 10.2746/042516409x478497pubmed: 20156251google scholar: lookup
  9. Matveyenko AV, Liuwantara D, Gurlo T. Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling. Diabetes 61, no. 9 (2012): 2269–2279.
    doi: 10.2337/db11-1462pmc: PMC3425431pubmed: 22688333google scholar: lookup
  10. Najjar SM, Yang Y, Fernström MA. Insulin Acutely Decreases Hepatic Fatty Acid Synthase Activity. Cell Metabolism 2, no. 1 (2005): 43–53.
    doi: 10.1016/j.cmet.2005.06.001pubmed: 16054098google scholar: lookup
  11. Lee W. The CEACAM1 Expression Is Decreased in the Liver of Severely Obese Patients With or Without Diabetes. Diagnostic Pathology 6, no. 1 (2011): 40.
    doi: 10.1186/1746-1596-6-40pmc: PMC3104481pubmed: 21569294google scholar: lookup
  12. Poy MN, Yang Y, Rezaei K. CEACAM1 Regulates Insulin Clearance in Liver. Nature Genetics 30, no. 3 (2002): 270–276.
    doi: 10.1038/ng840pubmed: 11850617google scholar: lookup
  13. Ghosh S, Kaw M, Patel PR, najjar S. Mice With Null Mutation of Ceacam1 Develop Nonalcoholic Steatohepatitis. Hepatic Medicine: Evidence and Research 2 (2010): 69–78.
    doi: 10.2147/HMER.S8902pmc: PMC3177946pubmed: 21949477google scholar: lookup
  14. Heinrich G, Ghadieh HE, Ghanem SS. Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non‐Alcoholic Fatty Liver Disease. Front Endocrinol 8 (2017): 8.
    doi: 10.3389/fendo.2017.00008pmc: PMC5266688pubmed: 28184213google scholar: lookup
  15. González-Casimiro CM, Merino B, Casanueva-Álvarez E. Modulation of Insulin Sensitivity by Insulin‐Degrading Enzyme. Biomedicine 9, no. 1 (2021): 86.
    doi: 10.3390/biomedicines9010086pmc: PMC7830943pubmed: 33477364google scholar: lookup
  16. Merino B, Fernández-Díaz CM, Parrado-Fernández C. Hepatic Insulin‐Degrading Enzyme Regulates Glucose and Insulin Homeostasis in Diet‐Induced Obese Mice. Metabolism, Clinical and Experimental 113 (2020): 154352.
    doi: 10.1016/j.metabol.2020.154352pmc: PMC8616598pubmed: 32916153google scholar: lookup
  17. Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of Insulin‐Degrading Enzyme Elicits Antipodal, Age‐Dependent Effects on Glucose and Insulin Tolerance. PLoS One 6, no. 6 (2011): e20818.
    doi: 10.1371/journal.pone.0020818pmc: PMC3111440pubmed: 21695259google scholar: lookup
  18. Rinella ME, Lazarus JV, Ratziu V. A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. Journal of Hepatology 79, no. 6 (2023): 1542–1556.
    doi: 10.1016/j.jhep.2023.06.003pubmed: 37364790google scholar: lookup
  19. Matsubayashi Y, Yoshida A, Suganami H. Role of Fatty Liver in the Association Between Obesity and Reduced Hepatic Insulin Clearance. Diabetes & Metabolism 44, no. 2 (2018): 135–142.
    doi: 10.1016/j.diabet.2017.12.003pubmed: 29395810google scholar: lookup
  20. Eslam M, Newsome PN, Sarin SK. A New Definition for Metabolic Dysfunction‐Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology 73, no. 1 (2020): 202–209.
    doi: 10.1016/j.jhep.2020.03.039pubmed: 32278004google scholar: lookup
  21. Targher G, Corey KE, Byrne CD, Roden M. The Complex Link Between NAFLD and Type 2 Diabetes Mellitus—Mechanisms and Treatments. Nature Reviews. Gastroenterology & Hepatology 18, no. 9 (2021): 599–612.
    doi: 10.1038/s41575-021-00448-ypubmed: 33972770google scholar: lookup
  22. Dunkel B, Wilford SA, Parkinson NJ. Severe Hypertriglyceridaemia in Horses and Ponies With Endocrine Disorders. Equine Veterinary Journal 46, no. 1 (2014): 118–122.
    doi: 10.1111/evj.12089pubmed: 23663085google scholar: lookup
  23. Mogg TD, Palmer JE. Hyperlipidemia, Hyperlipemia, and Hepatic Lipidosis in American Miniature Horses: 23 Cases (1990‐1994). Journal of the American Veterinary Medical Association 207, no. 5 (1995): 604–607.
    pubmed: 7649775
  24. Carroll CL, Huntington PJ. Body Condition Scoring and Weight Estimation of Horses. Equine Veterinary Journal 20, no. 1 (1988): 41.
    doi: 10.1111/j.2042-3306.1988.tb01451.xpubmed: 3366105google scholar: lookup
  25. Copas VEN, Durham AE. Circannual Variation in Plasma Adrenocorticotropic Hormone Concentrations in the UK in Normal Horses and Ponies, and Those With Pituitary Pars Intermedia Dysfunction. Equine Veterinary Journal 44, no. 4 (2012): 440–443.
    doi: 10.1111/j.2042-3306.2011.00444.xpubmed: 21848531google scholar: lookup
  26. Gastaldelli A. Measuring and Estimating Insulin Resistance in Clinical and Research Settings. Obesity 30, no. 8 (2022): 1549–1563.
    doi: 10.1002/oby.23503pmc: PMC9542105pubmed: 35894085google scholar: lookup
  27. Durham AE, Smitht KC, Newton JR. Development and Application of a Scoring System for Prognostic Evaluation of Equine Liver Biopsies. Equine Veterinary Journal 35, no. 6 (2003): 534–540.
    doi: 10.2746/042516403775467171pubmed: 14515951google scholar: lookup
  28. Bedossa P. Histological Assessment of NAFLD. Digestive Diseases and Sciences 61, no. 5 (2016): 1348–1355.
    doi: 10.1007/s10620-016-4062-0pubmed: 26874689google scholar: lookup
  29. Bedossa P, Poitou C, Veyrie N. Histopathological Algorithm and Scoring System for Evaluation of Liver Lesions in Morbidly Obese Patients. Hepatology 56, no. 5 (2012): 1751–1759.
    doi: 10.1002/hep.25889pubmed: 22707395google scholar: lookup
  30. Bao X, Ma X, Huang R. Knockdown of Hepatocyte Perilipin‐3 Mitigates Hepatic Steatosis and Steatohepatitis Caused by Hepatocyte CGI‐58 Deletion in Mice. Journal of Molecular Cell Biology 14, no. 8 (2022): mjac055.
    doi: 10.1093/jmcb/mjac055pmc: PMC9929509pubmed: 36107452google scholar: lookup
  31. Hodson L, Karpe F. Hyperinsulinaemia: Does It Tip the Balance Toward Intrahepatic Fat Accumulation?. Endocrine Connections 8, no. 10 (2019): R157–R168.
    doi: 10.1530/ec-19-0350pmc: PMC6826170pubmed: 31581129google scholar: lookup
  32. Li Y, Zheng T, Xiao S. Hepatocytic Ballooning in Non‐Alcoholic Steatohepatitis: Dilemmas and Future Directions. Liver International 43, no. 6 (2023): 1170–1182.
    doi: 10.1111/liv.15571pubmed: 37017559google scholar: lookup
  33. Szczepaniak LS, Nurenberg P, Leonard D. Magnetic Resonance Spectroscopy to Measure Hepatic Triglyceride Content: Prevalence of Hepatic Steatosis in the General Population. American Journal of Physiology. Endocrinology and Metabolism 288, no. 2 (2005): E462–E468.
    doi: 10.1152/ajpendo.00064.2004pubmed: 15339742google scholar: lookup
  34. Suagee JK, Corl BA, Crisman MV, Wearn JG, McCutcheon LJ, Geor RJ. De Novo Fatty Acid Synthesis and NADPH Generation in Equine Adipose and Liver Tissue. Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology 155, no. 3 (2010): 322–326.
    doi: 10.1016/j.cbpb.2009.11.019pubmed: 19962447google scholar: lookup
  35. Petersen MC, Shulman GI. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends in Pharmacological Sciences 38, no. 7 (2017): 649–665.
    doi: 10.1016/j.tips.2017.04.004pmc: PMC5499157pubmed: 28551355google scholar: lookup
  36. Leung YH, Kenéz Á, Grob AJ, Feige K, Warnken T. Associations of Plasma Sphingolipid Profiles With Insulin Response During Oral Glucose Testing in Icelandic Horses. Journal of Veterinary Internal Medicine 35, no. 4 (2021): 2009–2018.
    doi: 10.1111/jvim.16200pmc: PMC8295691pubmed: 34105193google scholar: lookup
  37. Adolph S, Schedlbauer C, Blaue D. Lipid Classes in Adipose Tissues and Liver Differ Between Shetland Ponies and Warmblood Horses. PLoS One 14, no. 3 (2019): e0207568.
    doi: 10.1371/journal.pone.0207568pmc: PMC6428305pubmed: 30897169google scholar: lookup
  38. Schedlbauer C, Blaue D, Gericke M. Impact of Body Weight Gain on Hepatic Metabolism and Hepatic Inflammatory Cytokines in Comparison of Shetland Pony Geldings and Warmblood Horse Geldings. PeerJ 7 (2019): e7069.
    doi: 10.7717/peerj.7069pmc: PMC6557249pubmed: 31211018google scholar: lookup
  39. Norton EM, Schultz NE, Rendahl AK. Heritability of Metabolic Traits Associated With Equine Metabolic Syndrome in Welsh Ponies and Morgan Horses. Equine Veterinary Journal 51, no. 4 (2019): 475–480.
    doi: 10.1111/evj.13053pubmed: 30472742google scholar: lookup

Citations

This article has been cited 1 times.
  1. Aboelmaaty AM, Ahdy AM, El-Khodery S, Elgioushy M. Investigations on metabolic diseases of horses in Egypt. Front Vet Sci 2025;12:1591090.
    doi: 10.3389/fvets.2025.1591090pubmed: 40901060google scholar: lookup
Subscribe to our newsletter
Join 100,129 horse owners like you who receive our email updates on horse health and nutrition.